Philip Kasten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Philip Kasten has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Philipp Niemeyer
2 shared publicationsReto Luginbühl
2 shared publicationsAa Moghaddam
1 shared publicationAj Suda
1 shared publicationAlexander Mehlhorn
1 shared publicationAnja Seckinger
1 shared publication
Latest Publications
- 1 November 2008
- Published by Elsevier in Acta Biomaterialia
- Vol. 4 (6) , 1904-1915
Porosity and pore size of β-tricalcium phosphate scaffold can influence protein production and osteogenic differentiation of human mesenchymal stem cells: An in vitro and in vivo study
- 1 November 2008
- Published by Elsevier in Acta Biomaterialia
- Vol. 4 (6) , 1904-1915
Porosity and pore size of β-tricalcium phosphate scaffold can influence protein production and osteogenic differentiation of human mesenchymal stem cells: An in vitro and in vivo study
- 23 October 2008
- Published by Forum Multimedia Publishing LLC
- Vol. 16, 47-55
Instant stem cell therapy: Characterization and concentration of human mesenchymal stem cells in vitro
In regenerative medicine, there is an approach to avoid expansion of the mesenchymal stem cell (MSC) before implantation. The aim of this study was to compare methods for instant MSC therapy by use of a portable, automatic and closed system centrifuge that allows for the concentration of MSCs. The main outcome measures were the amount of MSCs per millilitre of bone marrow (BM), clusters of differentiation (CD), proliferation and differentiation capacities of the MSC. A volume reduction protocol was compared to the traditional laboratory methods of isolation using a Ficoll gradient and native BM. Fifty millilitres of BM were obtained from haematologically healthy male Caucasians (n=10, age 8 to 49 years). The number of colony forming units-fibroblast (CFU-F)/ml BM was highest in the centrifuge volume reduction protocol, followed by the native BM (not significant), the centrifuge Ficoll (p=0.042) and the manual Ficoll procedure (p=0.001). The MSC of all groups could differentiate into the mesenchymal lineages without significant differences between the groups. The CD pattern was identical for all groups: CD13+; CD 44+; CD73 +; CD90+; CD105+; HLA-A,B,C+; CD14-; CD34-; CD45-; CD271-; HLA-DR-. In a further clinical pilot study (n=5) with 297 ml BM (SD 18.6), the volume reduction protocol concentrated the MSC by a factor of 14: there were 1.08 x 10(2) MSC/ml BM (standard deviation (SD) 1.02 x 10(2)) before concentration, 14.8 x 10(2) MSC/ ml BM (SD 12.4 x 10(2)) after concentration, and on average 296 x 10(2) MSC (SD 248.9 x 10(2), range 86.4-691.5 x 10(2)) were available for MSC therapy. The volume reduction protocol of the closed centrifuge allows for the highest concentration of the MSC, and therefore, is a promising candidate for instant stem cell therapy.
- 23 October 2008
- Published by Forum Multimedia Publishing LLC
- Vol. 16, 47-55
Instant stem cell therapy: Characterization and concentration of human mesenchymal stem cells in vitro
In regenerative medicine, there is an approach to avoid expansion of the mesenchymal stem cell (MSC) before implantation. The aim of this study was to compare methods for instant MSC therapy by use of a portable, automatic and closed system centrifuge that allows for the concentration of MSCs. The main outcome measures were the amount of MSCs per millilitre of bone marrow (BM), clusters of differentiation (CD), proliferation and differentiation capacities of the MSC. A volume reduction protocol was compared to the traditional laboratory methods of isolation using a Ficoll gradient and native BM. Fifty millilitres of BM were obtained from haematologically healthy male Caucasians (n=10, age 8 to 49 years). The number of colony forming units-fibroblast (CFU-F)/ml BM was highest in the centrifuge volume reduction protocol, followed by the native BM (not significant), the centrifuge Ficoll (p=0.042) and the manual Ficoll procedure (p=0.001). The MSC of all groups could differentiate into the mesenchymal lineages without significant differences between the groups. The CD pattern was identical for all groups: CD13+; CD 44+; CD73 +; CD90+; CD105+; HLA-A,B,C+; CD14-; CD34-; CD45-; CD271-; HLA-DR-. In a further clinical pilot study (n=5) with 297 ml BM (SD 18.6), the volume reduction protocol concentrated the MSC by a factor of 14: there were 1.08 x 10(2) MSC/ml BM (standard deviation (SD) 1.02 x 10(2)) before concentration, 14.8 x 10(2) MSC/ ml BM (SD 12.4 x 10(2)) after concentration, and on average 296 x 10(2) MSC (SD 248.9 x 10(2), range 86.4-691.5 x 10(2)) were available for MSC therapy. The volume reduction protocol of the closed centrifuge allows for the highest concentration of the MSC, and therefore, is a promising candidate for instant stem cell therapy.
- 1 October 2008
- Published by Elsevier in Biomaterials
- Vol. 29 (29) , 3983-3992
The effect of platelet-rich plasma on healing in critical-size long-bone defects
- 1 October 2008
- Published by Elsevier in Biomaterials
- Vol. 29 (29) , 3983-3992
The effect of platelet-rich plasma on healing in critical-size long-bone defects
- 19 August 2007
- Published by Springer Nature in Der Orthopäde
- Vol. 36 (9) , 855-861
Differenzialtherapie massiver Rotatorenmanschettenläsionen
Die erfolgreiche Therapie massiver Rotatorenmanschettenrupturen stellt hohe Anforderungen an den Schulterchirurgen, da das Behandlungskonzept an viele individuelle Patientenparameter adaptiert werden muss. Zunächst sollte entschieden werden, ob die Qualität der Muskel-/Sehneneinheit geeignet ist, eine direkte Naht durchzuführen. Falls die Degeneration zu weit fortgeschritten ist und zu viel Spannung bei der Reposition ausgeübt werden muss, kann man es evtl. bei einem partiellen Verschluss belassen, die Bicepssehne zur Defektdeckung verwenden oder einen lokalen Muskeltransfer mit z. B. dem M. subscapularis oder M. infraspinatus durchführen. Bei einem nicht mehr zu verschließenden Defekt und fehlenden Arthrosezeichen hat man die Wahl zwischen einer Tuberkuloplastik/subakromialen Dekompression bei älteren Patienten mit geringem funktionellem Anspruch oder einem Muskel-/Sehnentransfer bei Patienten 70 Jahre) kann die Implantation einer inversen Prothese erwogen werden. The treatment of massive rotator cuff tears must be adapted to the patient’s individual needs and preoperative parameters to achieve the best outcome. First, the shoulder surgeon has to determine whether a direct transosseous repair is possible. If there is not enough remaining tissue, the tissue is atrophic, and the tendon stump can be reduced only with great tension, one can use a margin convergence technique for partial closure, perform a biceps tendoplasty, or perform local tendon transfers with the subscapularis or infraspinatus muscle. If the defect cannot be sufficiently closed, elderly patients with low demands can be treated with tubercleplasty/subacromial decompression, whereas patients younger than 60 years with higher demands should receive muscle and tendon transfers. A balanced posterosuperior defect can be reconstructed by a deltoid muscle transfer, in contrast to an unbalanced one, which is best treated with an active transfer of the latissimus dorsi muscle and tendon. Anterosuperior defects can be addressed by a pectoralis muscle transfer. If the humeral head is superiorly migrated, if signs of osteoarthritis are present, and if the patient is older than 70 years, a reverse prosthesis can be implanted as a salvage procedure.
- 19 August 2007
- Published by Springer Nature in Der Orthopäde
- Vol. 36 (9) , 855-861
Differenzialtherapie massiver Rotatorenmanschettenläsionen
Die erfolgreiche Therapie massiver Rotatorenmanschettenrupturen stellt hohe Anforderungen an den Schulterchirurgen, da das Behandlungskonzept an viele individuelle Patientenparameter adaptiert werden muss. Zunächst sollte entschieden werden, ob die Qualität der Muskel-/Sehneneinheit geeignet ist, eine direkte Naht durchzuführen. Falls die Degeneration zu weit fortgeschritten ist und zu viel Spannung bei der Reposition ausgeübt werden muss, kann man es evtl. bei einem partiellen Verschluss belassen, die Bicepssehne zur Defektdeckung verwenden oder einen lokalen Muskeltransfer mit z. B. dem M. subscapularis oder M. infraspinatus durchführen. Bei einem nicht mehr zu verschließenden Defekt und fehlenden Arthrosezeichen hat man die Wahl zwischen einer Tuberkuloplastik/subakromialen Dekompression bei älteren Patienten mit geringem funktionellem Anspruch oder einem Muskel-/Sehnentransfer bei Patienten 70 Jahre) kann die Implantation einer inversen Prothese erwogen werden. The treatment of massive rotator cuff tears must be adapted to the patient’s individual needs and preoperative parameters to achieve the best outcome. First, the shoulder surgeon has to determine whether a direct transosseous repair is possible. If there is not enough remaining tissue, the tissue is atrophic, and the tendon stump can be reduced only with great tension, one can use a margin convergence technique for partial closure, perform a biceps tendoplasty, or perform local tendon transfers with the subscapularis or infraspinatus muscle. If the defect cannot be sufficiently closed, elderly patients with low demands can be treated with tubercleplasty/subacromial decompression, whereas patients younger than 60 years with higher demands should receive muscle and tendon transfers. A balanced posterosuperior defect can be reconstructed by a deltoid muscle transfer, in contrast to an unbalanced one, which is best treated with an active transfer of the latissimus dorsi muscle and tendon. Anterosuperior defects can be addressed by a pectoralis muscle transfer. If the humeral head is superiorly migrated, if signs of osteoarthritis are present, and if the patient is older than 70 years, a reverse prosthesis can be implanted as a salvage procedure.
- 1 January 2007
- Published by Mary Ann Liebert Inc in Tissue Engineering
- Vol. 13 (1) , 111-121
Comparison of Immunological Properties of Bone Marrow Stromal Cells and Adipose Tissue?Derived Stem Cells Before and After Osteogenic Differentiation In Vitro
Mesenchymal stem cells (MSCs) can be isolated from various tissues and represent an attractive cell population for tissue-engineering purposes. MSCsfrom bonemarrow(bonemarrowstromal cells [BMSCs]) are negative for immunologically relevant surface markers and inhibit proliferation of allogenic T cells in vitro. Therefore, BMSCs are said to be available for allogenic cell therapy. Although the immunological characteristics of BMSCs have been the subject of various investigations, those of stem cells isolated from adipose tissue (ASCs) have not been adequately described. In addition, the influence of osteogenic differentiation in vitro on the immunological characteristics of BMSCs and ASCs is the subject of this article. Before and after osteogenic induction, the influence of BMSCs and ASCs on the proliferative behavior of resting and activated allogenic peripheral blood mononuclear cells (PBMCs) was studied as a measure of the immune response (mixed lymphocyte culture). At the same points, the expression of immunologically relevant surface markers (e.g., major histocompatibility complex (MHC)-I, MHC-II, CD40, CD40L) was measured, and correlations between the different sets of results were sought. The pattern of surface antigen expression of BMSCs is the same as that of ASCs. Analogous to BMSCs, undifferentiated cells isolated from adipose tissue lack expression ofMHC-II; this is not lost in the course of the osteogenic differentiation process. In co-culture with allogenic PBMCs, both cell types fail to lead to any significant stimulation, and they both retain these characteristics during the differentiation process. BMSCs and ASCs suppress proliferation on activated PBMCs before and after osteogenic differentiation. Our results confirm that MSCs are immune modulating cells. These properties are retained even after osteogenic induction in vitro and seem to be similar in BMSCs and ASCs. Our results suggest that allogenic transplantation of BMSCs and ASCs would be possible, for example, in the context of tissue engineering.
- 1 January 2007
- Published by Mary Ann Liebert Inc in Tissue Engineering
- Vol. 13 (1) , 111-121
Comparison of Immunological Properties of Bone Marrow Stromal Cells and Adipose Tissue?Derived Stem Cells Before and After Osteogenic Differentiation In Vitro
Mesenchymal stem cells (MSCs) can be isolated from various tissues and represent an attractive cell population for tissue-engineering purposes. MSCsfrom bonemarrow(bonemarrowstromal cells [BMSCs]) are negative for immunologically relevant surface markers and inhibit proliferation of allogenic T cells in vitro. Therefore, BMSCs are said to be available for allogenic cell therapy. Although the immunological characteristics of BMSCs have been the subject of various investigations, those of stem cells isolated from adipose tissue (ASCs) have not been adequately described. In addition, the influence of osteogenic differentiation in vitro on the immunological characteristics of BMSCs and ASCs is the subject of this article. Before and after osteogenic induction, the influence of BMSCs and ASCs on the proliferative behavior of resting and activated allogenic peripheral blood mononuclear cells (PBMCs) was studied as a measure of the immune response (mixed lymphocyte culture). At the same points, the expression of immunologically relevant surface markers (e.g., major histocompatibility complex (MHC)-I, MHC-II, CD40, CD40L) was measured, and correlations between the different sets of results were sought. The pattern of surface antigen expression of BMSCs is the same as that of ASCs. Analogous to BMSCs, undifferentiated cells isolated from adipose tissue lack expression ofMHC-II; this is not lost in the course of the osteogenic differentiation process. In co-culture with allogenic PBMCs, both cell types fail to lead to any significant stimulation, and they both retain these characteristics during the differentiation process. BMSCs and ASCs suppress proliferation on activated PBMCs before and after osteogenic differentiation. Our results confirm that MSCs are immune modulating cells. These properties are retained even after osteogenic induction in vitro and seem to be similar in BMSCs and ASCs. Our results suggest that allogenic transplantation of BMSCs and ASCs would be possible, for example, in the context of tissue engineering.